Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RMWCH
ADC Name
SOT-102
Synonyms
SO- N102; SO-N102; SOT 102; SOT-102; SOT102; SOT102, SO- N102
   Click to Show/Hide
Organization
SCTbio as
Drug Status
Phase 1/2 (Terminated)
Indication
In total 1 Indication(s)
Pancreatic cancer
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Undisclosed
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
PNU-159682
  Payload Info 
Therapeutic Target
DNA topoisomerase 2-alpha (TOP2A)
  Target Info 
Linker Name
Pentaglycine-EDA (Non-cleavable)
  Linker Info 
Conjugate Type
Enzymatic Catalysis
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05525286
Phase 1
A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05525286  Clinical Status Phase 1
Clinical Description A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma.
References
Ref 1 A Multicentric Phase 1/2 Trial to Evaluate the Safety and Efficacy of SOT102 as Monotherapy and in Combination With Standard of Care Treatment in Patients With Gastric and Pancreatic Adenocarcinoma, NCT05525286